SOUTH SAN FRANCISCO, Calif.,
Aug. 10, 2020 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today
announced that its second quarter 2020 financial results will be
released on Friday, August 14,
2020.
Titan will host a live conference call to discuss the financial
results and provide a general business review the same day,
August 14, 2020, at 9:00 a.m. PT / 12:00 p.m.
ET. The call will be hosted by Sunil
Bhonsle, president and CEO; Kate
Beebe DeVarney, Ph.D., executive vice president and chief
scientific officer; Brian Crowley,
vice president of finance; Joe
Schrei, executive director, commercial operations;
Mike Fritz, national sales director;
and Marc Rubin, M.D., executive
chairman. A summary of the second quarter financial results and
other highlights will be included in a press release to be issued
prior to the call.
The live webcast and a replay of the call may be accessed by
visiting http://www.titanpharm.com/news/events. The call can also
be accessed by dialing 1-888-317-6003 (or 1-412-317-6061 from
outside the U.S.) ten minutes prior to the start time, and
providing passcode 8493149.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in
South San Francisco, CA, is a
commercial stage company developing proprietary therapeutics with
its ProNeura® long-term, continuous drug delivery technology. The
company's lead product is Probuphine® (buprenorphine) implant, a
novel and long-acting formulation of buprenorphine for the
long-term maintenance treatment of opioid dependence. Approved by
the U.S. Food and Drug Administration in May
2016, Probuphine is the first and only commercialized
treatment of opioid dependence to provide continuous,
around-the-clock blood levels of buprenorphine for six months
following a single procedure. The ProNeura technology also has the
potential to be used in developing products for treating other
chronic conditions such as Parkinson's disease and hypothyroidism,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please visit
www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine; the regulatory approval process;
Titan's ability to access capital; the development, testing,
production and marketing of our drug candidates; patent and
intellectual property matters; and strategic agreements and
relationships. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
CONTACTS:
Sunil Bhonsle
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-to-report-second-quarter-2020-financial-results-on-august-14-2020-301109397.html
SOURCE Titan Pharmaceuticals, Inc.